AptaBio Therapeutics Inc. (293780.KQ)
KRW 6500.0
(-3.56%)
KRW 6500.0
(-3.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 78.49 Million KRW | -1233.13% |
| 2022 | 37.2 Million KRW | -83.04% |
| 2021 | 219.35 Million KRW | -34.9% |
| 2020 | 336.96 Million KRW | -66.78% |
| 2019 | 1.01 Billion KRW | -30.24% |
| 2018 | 1.45 Billion KRW | 394.58% |
| 2017 | 294 Million KRW | -50.27% |
| 2016 | 591.17 Million KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -74.86 Million KRW | 196.29% |
| 2024 Q1 | -45.36 Million KRW | 94.03% |
| 2023 Q2 | 6.78 Million KRW | -56.9% |
| 2023 Q3 | 8.38 Million KRW | 23.62% |
| 2023 Q4 | -759.47 Million KRW | -9155.91% |
| 2023 Q1 | 15.73 Million KRW | -5.66% |
| 2023 FY | -421.6 Million KRW | -1233.13% |
| 2022 FY | 37.2 Million KRW | -83.04% |
| 2022 Q4 | 16.68 Million KRW | 249.39% |
| 2022 Q3 | 4.77 Million KRW | -41.93% |
| 2022 Q2 | 8.22 Million KRW | 9.22% |
| 2022 Q1 | 7.52 Million KRW | -34.87% |
| 2021 FY | 219.35 Million KRW | -34.9% |
| 2021 Q3 | 17.85 Million KRW | -78.8% |
| 2021 Q2 | 84.22 Million KRW | -20.33% |
| 2021 Q1 | 105.71 Million KRW | 456.86% |
| 2021 Q4 | 11.55 Million KRW | -35.25% |
| 2020 Q1 | 45.82 Million KRW | -80.72% |
| 2020 Q4 | 18.98 Million KRW | -65.75% |
| 2020 FY | 336.96 Million KRW | -66.78% |
| 2020 Q3 | 55.42 Million KRW | -74.42% |
| 2020 Q2 | 216.72 Million KRW | 372.93% |
| 2019 Q4 | 237.63 Million KRW | -5.19% |
| 2019 FY | 1.01 Billion KRW | -30.24% |
| 2019 Q3 | 250.63 Million KRW | -49.43% |
| 2019 Q2 | 495.6 Million KRW | 0.0% |
| 2018 Q4 | 38.75 Million KRW | -96.37% |
| 2018 Q3 | 1.06 Billion KRW | 313.92% |
| 2018 Q2 | 257.83 Million KRW | 0.0% |
| 2018 FY | 1.45 Billion KRW | 394.58% |
| 2017 FY | 294 Million KRW | -50.27% |
| 2016 FY | 591.17 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 82.98 Billion KRW | 99.905% |
| CMG Pharmaceutical Co., Ltd. | 43.7 Billion KRW | 99.82% |
| Celltrion Pharm, Inc. | 116.95 Billion KRW | 99.933% |
| Huons Global Co., Ltd. | 417.8 Billion KRW | 99.981% |
| DongKook Pharmaceutical Co., Ltd. | 405.04 Billion KRW | 99.981% |
| Enzychem Lifesciences Corporation | 3.29 Billion KRW | 97.617% |
| Humedix Co., Ltd. | 68.04 Billion KRW | 99.885% |
| Boditech Med Inc. | 76.7 Billion KRW | 99.898% |
| EuBiologics Co., Ltd. | 32.65 Billion KRW | 99.76% |
| FutureChem Co.,Ltd | 758.27 Million KRW | 89.648% |
| Huons Co., Ltd. | 285.93 Billion KRW | 99.973% |
| BNC Korea Co., Ltd. | 31.97 Billion KRW | 99.755% |